Skip to main content

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

Completed · Phase 3 · NCT04847557

Conditions: Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)

At a glance

Research payments reported, 2025
$118,055
U.S. investigators named
7
Sites paid
8
Planned or actual enrollment
731

About the trial

Sponsor
Eli Lilly and Company
Tested
Tirzepatide (drug), Placebo (other)
Dates
Started 2021-04-20; completion 2024-07-02
Results posted
Yes

The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.

From ClinicalTrials.gov, last updated 2025-08-20. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $118,055 in research payments for this study in 2025 (9 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • $64,722
  • Medical University of South Carolina $18,160
  • Los Angeles Biomedical $8,296
  • University of Pittsburgh Physicians $7,056
  • East Coast Institute for Research $5,935
  • Grace Research LLC $5,920
  • Morgan Medical Management and Consultants Inc $4,700
  • Carle Health Methodist Hospital, IL $3,000
  • Excel Medical Clinical Trials, LLC $266

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.